News

PS-Fertility, maker of a male fertility test, to establish HQ outside Charlottesville

Life sciences startup PS-Fertility Inc. will invest $1.4 million to build out a headquarters and laboratory in Albemarle County, the office of Virginia Gov. Glenn Youngkin announced Wednesday.

PS-Fertility is aiming to commercialize a male fertility diagnostic that was originally developed at the University of Virginia. The company will lease 4,000 square feet at 3030 Vision Lane, just south of Charlottesville’s city limits, for its headquarters and lab as well as a test kit assembly operation, according to the announcement. PS-Fertility said it plans to create 31 new jobs with the project.

The company’s diagnostic tests for the presence of a biomarker on sperm cells necessary for fertilization, which can offer information on male fertility. PS-Fertility plans to use an at-home collection model, where samples are mailed to the new lab from across the country.

CEO Kevin Combs said in a statement his company planned to launch “in the very near future.”

The Virginia Economic Development Partnership said it worked with Albemarle County to secure the project for the state. Its Virginia Jobs Investment Program will support PS-Fertility’s hiring efforts by providing consultative services and funding to support recruitment and training.

“Virginia is the birthplace of innovations, and PS-Fertility’s groundbreaking discovery demonstrates the importance of our entrepreneurial ecosystems that lead to new technologies and products, ultimately resulting in new jobs,” Caren Merrick, Virginia’s secretary of commerce and trade, said in a statement.

Read more here.

Recent News

08/10/2026

Expanding visibility with wearable blood pressure monitoring: CareTaker

In higher-risk patient populations, across all points of care, a patient’s condition can deteriorate quickly between routine vital sign checks, creating critical gaps in visibility and leaving clinical deterioration undetected between rounds. Continuous clinical-grade non-invasive blood pressure (CNIBP) monitoring, combined with hemodynamic trending, helps close these gaps by providing a more complete view of patient

08/10/2026

BIO-CAT Joins the Lallemand Family

BIO-CAT is pleased to join the Lallemand family as we begin an exciting new chapter together. Effective July 31, 2026, Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes & Microbials. Together, we are combining complementary expertise in enzymes, microbial technologies, fermentation, and life science innovation to create an even stronger platform for developing next-generation

08/05/2026

Virginia Catalyst Announces Opening of Grant Round 20

The Virginia Catalyst announced that it is accepting letters of intent (LOI) for Grant Round 20 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The Virginia Catalyst is excited to open Grant Round 20 to continue our support of Virginia’s